Clinical Trials for Mesothelioma Patients—Vaccine Therapy and GM-CSF: Outcome Measures

Read about the outcomes for a concurrent therapy for a current clinical trial to test vaccine therapy GM-CSF on mesothelioma patients. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.

Primary Outcome Measures:

• Safety and immunogenicity [ Designated as safety issue: Yes ]
• Immune response as measured by T-cell proliferative response, delayed-type hypersensitivity against WT-1 peptides, or ELISPOT [ Designated as safety issue: No ]

Secondary Outcome Measures:

• Antileukemic effects [ Designated as safety issue: No ]
• Clinical and molecular response [ Designated as safety issue: No ]
• Antitumor response as measured by CT scan based on RECIST criteria [ Designated as safety issue: No ]
• Toxicity as measured by NCI CTC v. 3.0 [ Designated as safety issue: Yes ]

Estimated Enrollment: 20

Study Start Date: October 2006

Estimated Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)

Courtesy of ClinicalTrials.gov, a service of the U.S. National Institutes of Health

If you or a loved one has been diagnosed with an Asbestos illness like mesothelioma, lung cancer or asbestosis, complete the form on this page to get a FREE and prompt review of your case by a leading Asbestos attorney. Weitz & Luxenberg is a leading mesothelioma law firm with a substantial history of success in asbestos exposure cases.